Editorial
HSP90 inhibitors as a future therapeutic strategy in diabetes-driven atherosclerosis
Inhibidores de HSP90 como futura estrategia terapéutica en la aterosclerosis asociada a diabetes
Manuel Vázquez-Carrera
Departamento de Farmacología, Toxicología y Química Terapéutica, Facultad de Farmacia y Ciencias de la Alimentación, Universidad de Barcelona, Instituto de Biomedicina de la Universidad de Barcelona (IBUB), Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III, Instituto de Investigación-Hospital Sant Joan de Déu
Read
1088
Timeswas read the article
287
Total PDF
801
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 12 | 28 | 3 | 31 |
| 2025 11 | 59 | 24 | 83 |
| 2025 10 | 38 | 14 | 52 |
| 2025 9 | 37 | 10 | 47 |
| 2025 8 | 23 | 16 | 39 |
| 2025 7 | 39 | 10 | 49 |
| 2025 6 | 35 | 6 | 41 |
| 2025 5 | 25 | 2 | 27 |
| 2025 4 | 14 | 3 | 17 |
| 2025 3 | 28 | 6 | 34 |
| 2025 2 | 22 | 6 | 28 |
| 2025 1 | 19 | 4 | 23 |
| 2024 12 | 19 | 1 | 20 |
| 2024 11 | 22 | 3 | 25 |
| 2024 10 | 10 | 3 | 13 |
| 2024 9 | 11 | 3 | 14 |
| 2024 8 | 21 | 6 | 27 |
| 2024 7 | 9 | 4 | 13 |
| 2024 6 | 13 | 6 | 19 |
| 2024 5 | 11 | 7 | 18 |
| 2024 4 | 12 | 10 | 22 |
| 2024 3 | 12 | 4 | 16 |
| 2024 2 | 12 | 7 | 19 |
| 2024 1 | 15 | 7 | 22 |
| 2023 12 | 12 | 8 | 20 |
| 2023 11 | 9 | 5 | 14 |
| 2023 10 | 9 | 4 | 13 |
| 2023 9 | 10 | 0 | 10 |
| 2023 8 | 4 | 7 | 11 |
| 2023 7 | 11 | 5 | 16 |
| 2023 6 | 6 | 4 | 10 |
| 2023 5 | 9 | 2 | 11 |
| 2023 4 | 6 | 3 | 9 |
| 2023 3 | 12 | 5 | 17 |
| 2023 2 | 17 | 5 | 22 |
| 2023 1 | 20 | 7 | 27 |
| 2022 12 | 25 | 2 | 27 |
| 2022 11 | 19 | 8 | 27 |
| 2022 10 | 10 | 6 | 16 |
| 2022 9 | 15 | 4 | 19 |
| 2022 8 | 16 | 12 | 28 |
| 2022 7 | 6 | 8 | 14 |
| 2022 6 | 5 | 7 | 12 |
| 2022 5 | 12 | 4 | 16 |
| 2022 4 | 10 | 6 | 16 |
| 2022 3 | 10 | 3 | 13 |
| 2022 2 | 6 | 6 | 12 |
| 2018 4 | 5 | 1 | 6 |
| 2018 3 | 3 | 0 | 3 |
Show all